|

Abiraterone Clinical Trials

17 actively recruiting trials across 15 locations

Also known as: 154229-19-3, 16-dien-3beta-ol, 17-(3-Pyridyl)androsta-5, Abiraterone acetate, CB 7598 +3 more

Pipeline

Phase 1: 2Phase 2: 6Phase 3: 5Phase 1/2: 4

Top Sponsors

  • Novartis Pharmaceuticals3
  • Amgen3
  • University of Washington1
  • University of California, Davis1
  • Telix Pharmaceuticals (Innovations) Pty Limited1

Indications

  • Cancer17
  • Metastatic Castration-resistant Prostate Cancer4
  • Metastatic Hormone-sensitive Prostate Cancer (mHSPC)2
  • Stage IV Prostate Cancer AJCC v82
  • Prostate Cancer2

Birmingham, Alabama2 trials

A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer

Central Alabama Research

Phase 3
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

University of Alabama at Birmingham

Phase 3

Other1 trial

A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
Phase 1/2

Anchorage, Alaska1 trial

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

Anchorage Associates in Radiation Medicine

Phase 3

Gilbert, Arizona1 trial

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

Banner MD Anderson Cancer Center

Phase 3

Phoenix, Arizona1 trial

Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial

Mayo Clinic in Arizona

Phase 2

Tucson, Arizona1 trial

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

Research Site 111

Phase 1/2

Duarte, California1 trial

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

City of Hope National Medical Center

Phase 1

La Jolla, California1 trial

An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

University of California San Diego - Moores Cancer Center

Phase 2

Orange, California1 trial

The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

Chao Family Comprehensive Cancer Centre

Phase 3

Sacramento, California1 trial

Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer

University of California Davis Comprehensive Cancer Center

Phase 2

San Francisco, California1 trial

A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)

UCSF Medical Center at Mission Bay ( Site 0034)

Phase 1/2

Tampa, Florida1 trial

Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer

Moffitt Cancer Center

Phase 2

Iowa City, Iowa1 trial

A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer

Holden Comprehensive Cancer Center

Phase 2

Wichita, Kansas1 trial

TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Wichita Urology Group PA

Phase 1/2

Boston, Massachusetts1 trial

Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer

Dana Farber Cancer Institute

Phase 1

Pittsburgh, Pennsylvania1 trial

Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study

University of Pittsburgh Cancer Institute (UPCI)

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.